Tanja Andrea Gruber, MD
Pediatric Hematology-Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gruber’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A89115 · Current
Licensed to practise in California · since 2020 · expires 2028-04-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 45680Medical Doctor · since 2009 · expires 2021-08-31Specialty on the licence: HematologyVoluntarily RetiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Hematology-Oncology
- American Board of Pediatrics - Pediatrics
Education
- University of So CaliforniaLOS ANGELES, CA · 2003
Residency and fellowship
- Childrens Hospital Los AngelesLOS ANGELES, CA · 2006–2009
- Childrens Hospital Los AngelesLOS ANGELES, CA · 2004–2006
- Childrens Hospital Los AngelesLOS ANGELES, CA · 2003–2004
Medicaid work
$14,343 in 2024
Medicaid paid $14,343 for 133 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 58 | $8,644 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 44 | $3,700 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 31 | $1,998 |
| 2024 | 133 | 3 | 14 | $14,343 |
| 2022 | 99 | 2 | 14 | $7,727 |
| 2020 | 39 | 1 | 13 | $2,268 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 78 | $5,109 |
| Return visit (30+ min) | 21 | $2,618 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 39 | $2,268 |
Money from drug and device companies
$50 in 2025
| 2025 | 1 | 1 | None | $50 |
| 2019 | 1 | 1 | None | $106 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | None | $50 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-12-07 | None | $50 |
See earlier years (2019)
2019: $106
| Pfizer | None | $106 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia · 2021 | Their institution | $78,431 |
| PFIZER INC. · A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia · 2020 | Their institution | $62,247 |
| PFIZER INC. · A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia · 2022 | Their institution | $55,895 |
| PFIZER INC. · A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia · 2025 | Their institution | $49,386 |
| Takeda Pharmaceuticals U.S.A., Inc. · Open-Label Phase 1 Study To Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously To Pediatric Patients Aged 0 To <18 Years With Relapsed Or Refractory Acute Lymphoblastic Leukemia, With Or Without Extramedullary Disease, Or Relapsed Or Refractory Lymphoblastic Lymphoma · 2020 | Their institution | $24,550 |
| Amgen Inc. · Tini 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II · 2024 | Their institution | $21,723 |
| PFIZER INC. · A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia · 2024 | Their institution | $15,982 |
| Amgen Inc. · Tini 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II · 2025 | Their institution | $4,958 |
Professional record
- NPI
- 1457471567
- Licence
- CA A89115, TN 45680California A89115: Current · expires 2028-04-30Tennessee 45680: Voluntarily Retired
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 262 Danny Thomas Pl # Ms 515, Memphis, TN, 38105
- NPI first listed
- 2007-03-30
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4650 W Sunset Blvd, Los Angeles, CA, 90027 · 262 Danny Thomas Pl, Memphis, TN, 38105